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DUX4Facioscapulohumeral muscular dystrophy (FSHD) is characterized by a typical and asymmetric pattern ofmuscle
involvement and disease progression. Two forms of FSHD, FSHD1 and FSHD2, have been identiﬁed displaying
identical clinical phenotype but different genetic and epigenetic basis. Autosomal dominant FSHD1 (95% of pa-
tients) is characterized by chromatin relaxation induced by pathogenic contraction of a macrosatellite repeat
called D4Z4 located on the 4q subtelomere (FSHD1 patients harbor 1 to 10 D4Z4 repeated units). Chromatin re-
laxation is associated with inappropriate expression of DUX4, a retrogene, which in muscles induces apoptosis
and inﬂammation. Consistent with this hypothesis, individuals carrying zero repeat on chromosome 4 do not
develop FSHD1. Not all D4Z4 contracted alleles cause FSHD. Distal to the last D4Z4 unit, a polymorphic site
with two allelic variants has been identiﬁed: 4qA and 4qB. 4qA is in ciswith a functional polyadenylation consen-
sus site. Only contractions on 4qA alleles are pathogenic because the DUX4 transcript is polyadenylated and
translated into stable protein. FSHD2 is instead a digenic disease. Chromatin relaxation of the D4Z4 locus is
caused by heterozygousmutations in the SMCHD1 gene encoding a protein essential for chromatin condensation.
These patients also harbor at least one 4qA allele in order to express stable DUX4 transcripts. FSHD1 and FSHD2
may have an additive effect: patients harboring D4Z4 contraction and SMCHD1mutations display a more severe
clinical phenotype than with either defect alone. Knowledge of the complex genetic and epigenetic defects
causing these diseases is essential in view of designing novel therapeutic strategies. This article is part of a Special
Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is the most
common myopathy found in adults, with an overall incidence of more
than 1:10,000 (source: Orphanet). It is classiﬁed among progressive
muscular dystrophies, characterized bymuscular ﬁber necrosis and de-
generation giving rise to progressivemuscularweakness and atrophy. A
certain degree of T cell inﬂammation has been described in an FSHD
patient's muscles and inﬂammation is thought to participate to the
cascade of events inducing muscle degeneration [1,2].
FSHD is a genetically heterogeneous disorder and its genetic bases
are unique and involve both genetic and epigenetic alterations. The
vast majority of FSHD, indeed, are transmitted as an autosomal domi-
nant trait with the disease locus mapping to the subtelomeric region
of chromosome 4q. This form has been termed FSHD1. However someuscular Diseases: Pathology and
dies Neuromusculaires, Hôpital
02 Nice, France. Tel.: +33 492
e.fr (S. Sacconi).families, with an undistinguishable clinical phenotype display a more
complex pattern of inheritance and a distinct genetic defect. This second
form is termed FSHD2. In this review, we will discuss the clinical
features, the molecular bases of FSHD, and the therapeutic strategies
that are currently being tested.2. Clinical features
FSHD was ﬁrst described in the late 1800s by Louis Landouzy and
Joseph Dejerine [3]. Their reports contain an accurate description of
the key features of the disease, including early involvement of facial
muscles, progressive weakness and atrophy of scapular and humeral
muscles, and clinical variability among affected members of the same
family.
Disease onset is usually before the second decade; earlier onset is
associated with more rapid progression and higher severity, indeed
most of the FSHD patients who become wheelchair-bound have had a
childhood onset of the disease [4]. These FSHD patients are also keener
to develop extra muscular complication of the disease such as central
nervous system (CNS) involvement [5–7], retinal telangiectasia [8]
and hearing impairment.
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however some obligate carriers remain asymptomatic throughout
their lives [10–12]. Larger studies are needed to clarify the actual
penetrance of the disease. A marked intra- and interfamilial variability
is remarkable in the clinical presentation; usually females display later
onset and a slower progression. Moreover a higher proportion of
asymptomatic carriers are females [13]. Interestingly, in women
expressing the disease, the severity becomes more important after
menopause and no difference between male and female populations
has been reported in a genotype/phenotype correlation study of elder
patients (Sacconi, unpublished results). These ﬁndings suggest a
possible protective role of estrogen that has to be investigated in further
studies.
The main characteristics of muscular involvement in FSHD are
asymmetry, selectivity, and the progression proﬁle. Asymmetric in-
volvement, which is rarely encountered in other limb girdle muscular
dystrophies, is almost always present in FSHD patients and it is not re-
lated to handedness [14]. Muscular weakness usually spreads from the
face to the limbs, but progression is extremely variable. Selectivity of
muscular involvement is another peculiar characteristic of FSHD
(Fig. 1).
One third of patients will display only facial and shoulder muscle
weakness; in the remaining patients, weakness will spread to anterior
armmuscles, abdominal muscles and/or pelvic girdle muscles. Respira-
tory muscle weakness is not very frequent and is usually secondary to
thoracic deformations [15]. Restrictive respiratory muscle involvement
seems more frequent in FSHD2 [16]. However, the high prevalence of
sleep-disordered breathing was noted in patients with FSHD, indepen-
dently to the severity of muscular involvement requiring, in a minority
of cases, positive airway pressure [17].
Weakness usually progresses very slowly, allowing FSHD patients to
adapt and compensate muscular deﬁciencies, at least at the functional
level. In some patients, course is characterized by relapses followed by
long intervals of stable clinical conditions. The majority of patients will
retain the ability to walk, although many experience severe limitations
in everyday life activities. 10–20% of FSHD patients are wheelchair-
bound [9,18]. Life expectancy is not signiﬁcantly reduced, except for
early onset patients with the more severe forms, or when correct care
is not instituted.
Although FSHD is considered as a skeletal muscle speciﬁc disease,
extra muscular involvement has been reported. Sensorineural hearing
loss seems to be quite frequent, since in various studies, it has been
reported in 25 to 65% of patients [8,18,20,21] even though most of the
patients present with subclinical impairment; severe hearing loss is
more frequent in early onset patients [7]. Cardiomyopathy is rare [9],
however, some patients may present with heart conduction defects
[22]. Dysphagia has been described in patients with advanced stagesFig. 1. Selectivity of muscular involvement in FSHD patient. Different levels of muscular dyst
changes, increased percentage of internalized nuclei, increased ﬁber type variability with some
advanced dystrophic changes.of FSHD showing mild involvement of the jaw and lingual muscles
[23]. It is particularly frequent in early onset patients and in some
cases required gastrostomy [7]
Retinal telangiectasias may also be found in a limited number
of FSHD patients; most of the time, they are asymptomatic. In rare
cases, it may result in Coat's-like disease associated to abrupt retinal
detachment with severe consequences up to irreversible blindness
[19]. Except for one, all FSHD patients, who were reported in literature
with a Coat's-like disease carry a contracted D4Z4 allele of less than
15 kb. Most of them are women [8].
CNS involvement is usually not described in FSHD patients, with the
exception of some early onset cases who presented mental retardation
and epilepsy [5–7].
However, studies evaluating subclinical CNS involvement in FSHD
patients have shown an increased frequency of cerebral white matter
lesions, motor cortex excitability abnormalities [24] and loss of gray
matter in the left precentral cortex, and in the right fronto-polar and
anterior cingulate regions [25]. FSHD2 patients do not seem to display
a signiﬁcantly different clinical phenotype compared to FSHD1, in
terms of the pattern of muscular weakness and the frequency of extra
muscular involvement except for retinal telangectasia that has never
been described in these patients [26].
To date, no early onset FSHD2 patient has been reported in literature,
besides a patient carrying both FSHD1 and FSHD2whobegan to develop
symptoms in early childhood [12].
Studies are ongoing in FSHD2patients, to establish the clinical effects
of hypomethylation found on other regions of the genome [27] and
which may also be present in the relatives without the 4qA allele and
consequently not displaying muscular features of FSHD.
3. Genetic aspects: FSHD1
In most patients, FSHD is inherited as an autosomal dominant trait
(FSHD1) and de novo cases accounting for around 25% [28,29] of
patients. Often de novo cases are in the mosaic form. Linkage studies
on large families have mapped the disease locus to the subtelomeric re-
gion of chromosome 4, more speciﬁcally at 4q35-qter [30–32]. This
chromosomal region lacked classical genes but contains amacrosatellite
repeat comprised of an array of repeated 3.3 kb units, called D4Z4.
Analysis of a large population of healthy subjects and FSHD patients
established in the past that the number of D4Z4 repeated units on
chromosome 4 varies in the general population between 11 and 110,
whereas FSHD patients carry a contracted allele from 1 to 10 repeated
units [29,33].
There is a rough correlation between D4Z4 repeat number, age of
onset and severity of clinical phenotype. Patients carrying the lower
number of repeats are the most severely affected [34], while thoserophy can be found in different muscles of an FSHD patient. A) Deltoid; mild myopathic
(partially) atrophic muscle ﬁbers. B) Biceps: moderate myopathic changes. C) Trapezius:
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besides a few exceptions.
FSHD1 was therefore deﬁned as a “repeat contraction” disorder. It
should be noted that unlike repeat expansion disorders, FSHD1 does
not display the phenomenon of anticipation, and the size of the
contracted D4Z4 arrays is stable within families.
The clinical diagnosis of FSHD is conﬁrmed by molecular analysis,
bypassing the need formuscle biopsy inmost cases. Standardmolecular
testing for FSHD1 demonstrates the presence of a contraction of the
D4Z4 repeated units in one copy of 4q35.
The molecular diagnosis of FSHD1 is performed by a classical
technique, consisting of a Southern blot [29,33] using the p13E-11
probe, on linear gel electrophoresis (LGE), which recognizes a region
proximal to the D4Z4 locus on chromosome 4, after a double digestion
of the DNA with EcoRI and BlnI enzymes. Normal individuals usually
harbor fragments larger than 38 kb.
The high homology between chromosomes 10q and 4q (98% of the
sequence is identical) is the basis for the relatively frequent genomic
rearrangements affecting this region. D4Z4 repeats with a typical 10q
sequence have been observed on 4q chromosomes in 10% of the
Dutch population. The reverse conﬁguration is also quite frequent [35,
36], demonstrating that homologous domains 4q and 10q are highly
dynamic and that FSHD is not due to an alteration of a speciﬁcmolecular
composition of D4Z4 elements but to their structural organization on
the 4q35 region [37,38].
Rearrangements between 4q and 10q chromosomesmay complicate
the diagnosis of FSHD1, generating false negative or false positive
results and must be researched in all cases when clinical data do not
correspond to genetic results.
A recent study on single-nucleotide polymorphisms localized on the
D4Z4 locus allowed the identiﬁcation of nine different haplotypes [39]
in the general population. Only a few of them, all 4qA types, are associ-
ated with the disease. The most frequent among these “permissive”
haplotypes is 4A161 [40–43]. In a reduced percentage of cases, around
5%, D4Z4 allele contraction on chromosome 4 may not be detected
with the standard analysis because of the presence of a proximal
deletion of D4Z4 repeated units including the p13E-11 region [44,45].
The high incidence of somatic mosaicism in de novo patients may be
also a source of diagnostic errors because they are under recognized by
classical LGE. These patients are sporadic cases and show usually mild
phenotypes or atypical clinical pictures [46].
The use of pulse ﬁeld gel electrophoresis (PFGE) is highly recom-
mended, as well as 4qA and 4qB determination. In dubious cases, it is
important to search for rearrangements between chromosomes 10
and 4 and proximal deletions including the p13E-11 probe region by
using speciﬁc protocols, including additional restriction enzyme
digestion combined or not with additional probes.
These approaches are however technically challenging and there are
efforts aimed at simplifying the task. One of these is molecular combing,
an approach based on ﬂuorescent in situ hybridization, which has shown
promising results, but it has not yet entered clinical practice [47]. Another
proposed method employs genotyping of a set of SNP in this region and
allows avoiding Southern blot studies in selected cases and could be
useful for prenatal or preimplantation genetic diagnosis [48].
In a recent large-scale population study the current criteria for
FSHD1 molecular analysis were challenged, in particular concerning
the penetrance of this disease and its association with the 4qA allelic
variant. Indeed, among the 801 healthy subjects analyzed in this
study, 16 (2.1%) were found to carry a 4qA contracted D4Z4 allele on
chromosome 4qA of less than 11 repeats.
In 10 of these healthy subjects, the incomplete of penetrance of
borderline alleles comprised between 7 and 10 repeats may explain
the lack of clinical manifestations. In fact, borderline alleles may be
more frequent than currently thought in the general population and
could result in a clinical phenotype only in the presence of genetic,
epigenetic, or environmental modiﬁers.The interpretation of the results obtained in the remaining 6 healthy
subjects carrying 4–6 repeated units on permissive 4qA chromosomes is
more complicated. The lack of precise clinical data and the fact that non-
pathogenic chromosome 4 and 10 rearrangements could have been
missed by the testing protocol may explain these results, but further
genetic and clinical studies are warranted to clarify this issue.
In the same article, 3 over 223 unrelated FSHD patients were found
to carry a 4qB allele in association with the FSHD phenotype. We have
demonstrated previously that several diseases can mimic very closely
FSHD in the presence of a 4qB-contracted allele and must be excluded
before concluding for FSHD diagnosis [49,50].
4. Pathophysiology of FSHD1 and role of the dux4 gene
Monosomy 4q is not associated with the appearance of a clinical
phenotype and at least one D4Z4 repeat from chromosome 4 is neces-
sary to develop FSHD [51].
This ﬁnding brought the attention on the structure of the D4Z4 re-
peats on chromosome 4. Every D4Z4 repeat contains an open reading
frame (ORF) coding for DUX4 [52–56], a retrogene which ancestrally
originated from the retrotransposition of the mRNA of DUX4c. DUX4c
is still present in the majority of mammals [57] but has been lost in
the primate lineage.
DUX4 encodes for a putative transcription factor that contains two
homeobox domains. It is normally expressed in human testis andduring
early development, but it is repressed during cellular differentiation.
DUX4 expression in muscle cells induces the expression of germline
genes and immunemediators, but also of retrotransposons, endogenous
retrovirus elements, and pericentromeric satellite HSATII sequences
[58,59]. Some of these elements may create alternative promoters for
genes causing production of non-physiological transcripts, long non-
coding RNAs, or antisense transcripts. All these factors are likely to be
involved in the downstream cascade of intracellular and extracellular
events leading to muscle degeneration. Since DUX4 expression is
transient and is limited to a speciﬁc time window, these transcripts
could also be used as biomarkers of the disease.
Therefore FSHD is associated with the failure to maintain complete
suppression of DUX4 expression in differentiated skeletal muscle (and
other tissues). Overexpression of DUX4 in a zebraﬁsh model recapitu-
lates the features of FSHD thus conﬁrming the relationship between
DUX4 and FSHD and underlining the importance of DUX4 expression
in FSHD pathophysiology during development [60]. More recently
transgenic mice carrying D4Z4 arrays from an FSHD1 allele and from a
control allele have been generated recapitulating several genetic and
epigenetic features seen in FSHD patients: high DUX4 expression levels
in the germline, (incomplete) epigenetic repression in somatic tissue,
and FSHD-speciﬁc variegated DUX4 expression in sporadic muscle
nuclei associated with D4Z4 chromatin relaxation [61].
The exact relationship betweenD4Z4 repeat contraction on chromo-
some 4 and overexpression of DUX4 was clariﬁed only recently. A
detailed analysis of the 4q subtelomeric region revealed that only the
most telomeric D4Z4 repeat can produce DUX4 transcripts. In fact
D4Z4 contains only exons 1 and 2 of DUX4, while the rest of the gene
is located on the non-repetitive region distal to the last D4Z4 repeat.
This region includes also a sequence termed pLAM that contains a
polyadenylation consensus sequence that is necessary for the proper
maturation of DUX4 transcripts. This consensus is functional only in
the permissive 4qA chromosomes but not in 4qB or 10q chromosomes.
Therefore only DUX4 transcripts originating from the last repeat on
the 4qA chromosome can be polyadenylated and are stable (and can
be translated into protein) while those expressed from 4qB or 10q
chromosomes are rapidly degraded [62] (Fig. 2).
The size of the 4q telomere could also be important in modulating
DUX4 expression, especially in thepresence of a contractedD4Z4 repeat.
Shortening of the telomeric repeatswith each cell division could explain
disease progression. Using a cell culture model, Stadler et al. [63]
Fig. 2. Structure of the 4q subtelomeric region. A) Comprehensive view of the 4q subtelomeric regionwith the D4Z4macrosatellite repeat. The p13E-11 is the probe commonly employed
for Southern blot analysis of patients. 4qA and 4qB are allelic. B) Arrangement of DUX4 in D4Z4 repeats. Each unit contains sequences corresponding to DUX4 exons 1 and 2. Exon 3 is
located outside of the repeated region, therefore only the last unit can be expressed (if located on a permissive chromosome). C) Structure of the DUX4 gene and of its two transcripts
found in muscle.
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upregulation of DUX4-ﬂ expression in cells from FSHD subjects. Overex-
pression is inversely proportional to telomere length and this effect is
observed long before terminal telomere shorteningwould induce repli-
cative senescence.
To make matters even more complicated, besides the full length
DUX4 transcript (DUX4-ﬂ) a shorter form exists (DUX4-s) that lacks a
part of exon 1 because of a non-canonical alternative splice consensus
within the DUX4 ORF [64]. DUX4-s lacks the C-terminal of DUX4-ﬂ and
does not elicit apoptosis when expressed. Its physiological function is
still unclear.
DUX4-ﬂ is produced from the last D4Z4 unit in early stem cells, while
in differentiated tissues, the D4Z4 array is normally associated with his-
tone H3 with a trimethylated lysine at position 9 which represses DUX4
expression [65]. The transcripts that escape repression, are preferentially
spliced using the alternative splicing consensus, producing DUX4-s in-
stead of DUX4-ﬂ. Contraction of the D4Z4 arrays inhibits the conversion
to repressive chromatin, andDUX4 is transcribed, and is spliced using the
canonical exon 1 consensus, thereby forming DUX4-ﬂ.
The speciﬁc de-repression of DUX4 transcription in skeletal muscle
and not, or only marginally, in other adult tissues in FSHD is explained
by the presence upstream of the D4Z4 array of two muscle speciﬁc
enhancer sequences (DME1 and DME2) which interact with the DUX4promoter in vivo and are able to activate DUX4-ﬂ expression in
myocytes but not in other cell types [66].
Therefore, several events concur to determine FSHD1: 1) there must
be a contraction of the D4Z4 repeat array on 4q35; 2) the contraction is
associatedwith chromatin relaxation andhypomethylation of the region;
3)DUX4 is transcribed; and 4) the transcriptmust be polyadenylated and
this can occur only when contractions affect 4qA type chromosomes.
In the testis (and only in the testis) other polyadenylation sites,
distal to the pLAM region, are activated, thereby allowing the expression
of DUX4 also from 4qB chromosomes [64]. This model accounts also for
the observation that deletions of the entire D4Z4 array are not associat-
ed with FSHD and excludes a major role in the pathogenesis of the
disease of transcriptional deregulation of neighboring genes [51].
5. FSHD2
A small proportion of patients (around5–10%)with features of FSHD
do not harbor a contraction of the 4q35 D4Z4 array and they often have
a complex pattern of inheritance. The molecular basis of this second
form of FSHD, termed FSHD2, has remained obscure for many years.
Since FSHD1 patients have been shown to display hypomethylation
restricted to the D4Z4 contracted allele on chromosome 4 [67] patients
presentingwith an FSHDphenotype carrying a normal sized D4Z4 allele
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tients, called FSHD2, were found to harbor at least one chromosome
4qA and displayed a marked hypomethylation of chromosome 4 sug-
gesting a common pathophysiological pathway in both conditions [68].
Chromatin studies in FSHD2 patients showed the presence of D4Z4
chromatin relaxation leading toDUX4-ﬂ expression [43]. Interestinghy-
pomethylation was found also on chromosome 10q (which is normally
methylated in FSHD1 patients) and in other regions of the genome [27].
In FSHD2 families, 4q hypomethylation segregated independently
from the disease; only patients who had 4q hypomethylation and at
least one 4qA allele developed FSHDwhile those with 2 4qB type alleles
were healthy. This was consistent with a genetic defect impairing
chromatin condensation and methylation independent from the D4Z4
arrays, affecting also other genomic targets. This defect was identiﬁed
in 2012 thanks to a next generation sequencing approach. FSHD2
patients were shown to harbor heterozygous mutations in SMCHD1 on
chromosome 18p11.32, a gene essential for the inactivation of the X
chromosome. Mutations apparently cause a loss of function of the pro-
tein and the pathogenesis of the disease is likely due to SMCHD1
haploinsufﬁciency. Therefore FSHD2 is a digenic disorder, which
requires both a mutation inactivating one copy of SMCHD1 and a
permissive 4qA allele (Fig. 3).
In conclusion, both FSHD1 and FSHD2 result from the inappropriate
expression of DUX4 in differentiated tissues. In FSHD1, this occurs
because the contracted D4Z4 repeats cannot form repressive
heterochromatine, and in FSHD2 because one of the effector genes re-
quired for methylation (and repression of DUX4) is haploinsufﬁcient.
In both situations, the defect must be associated with a 4qA allele (in
the case of FSHD1, the contraction must be in cis with the 4qAFig. 3. Genetic and epigenetic mechanisms of FSHD1, FSHD2, and FSHD1 + 2. A) In normal ind
methylated and has a heterochromatic structure. DUX4 transcription may take place but tra
array (1–10 repeats) on a permissive chromosome causes hypomethylation and chromatin rela
Polyadenylation signal (PAS) is located distally to the D4Z4 last repeat. C) FSHD2 patients harb
SMCHD1 gene on chromosome 18. Haploinsufﬁciency of SMCHD1 causesmarked hypomethylati
from permissive 4q alleles can be stabilized by polyadenylation. D) FSHD1+ 2 patients, presen
some and a SMCHD1mutation, with an additive effect on D4Z4 hypomethylation and chromatpolymorphism) in order for the DUX4 transcripts to be polyadenylated
and translated into protein.
Finally, although there are known phenocopies of FSHD, which may
be associated to mutations in other genes (CAPN3, VCP) [46], there are
still patients with an FSHD-like phenotype who lack a clear molecular
defect. Some of them show an extended hypomethylation but no
SMCHD1 mutation. Although for some patients, technical issues may
limit the detection ofmutation in the SMCHD1 gene, another interesting
possibility is that mutations in other genes involved in chromatinmain-
tenance may account for these cases.
6. Combination of FSHD1 and FSHD2
We have recently identiﬁed a number of patients harboring 9 D4Z4
repeated units on 4qA chromosomes who presented with very severe
clinical phenotypes compared to the number of residual repeats.
These patients had profound hypomethylation on chromosome 4qA
and were found to harbor SMCHD1mutations. Detailed analysis of the
families revealed, as expected, that the two defects may segregate inde-
pendently in the pedigrees and that patients affected by either defect
alone presented with a mild form of FSHD1 or FSHD2 (in this case
only if another 4qA allele was present), while a severe phenotype was
observed if both defects were transmitted to the offspring. The D4Z4
contraction and SMCHD1 mutations have an additive effect on D4Z4
methylation resulting in a further increase of DUX4-ﬂ overexpression,
and thus a more severe phenotype. In this view, the SMCHD1mutations
are amodulator of the severity of theD4Z4 contraction. But the opposite
is also true: the D4Z4 contraction modulates the severity of the pheno-
type associated with SMCHD1mutations.ividuals the 4q35 region comprises an array containing 11–100 D4Z4 repeats. It is highly
nscripts are rapidly degraded. B) In FSHD1 patients, pathogenic contraction of the D4Z4
xation of this region.DUX4 is transcribed and transcripts are stabilized by polyadenylation.
or a normal sized D4Z4 repeat allele on a permissive chromosome 4 but a mutation of the
on and chromatin relaxation on 4q35, thus increasingDUX4 transcription. Only transcripts
t with a pathogenic D4Z4 contracted allele on 4q35 (b11 repeats) in a permissive chromo-
ine relaxation and an overexpression of DUX4 transcripts.
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or borderline D4Z4 contractions could act as genetic modiﬁers for other
diseases.7. Therapy and management
No etiological therapy is available, to date, for FSHD patients, mainly
due to the fact that the physiopathologicalmechanismof FSHD is still not
completely clear. Nevertheless, a number of pharmacological strategies
have been tested in order to slow down or stop disease progression.
Since, around 40% of FSHD muscle biopsies show T cell inﬂammatory
inﬁltrate, corticosteroids were tried in a number of cases without any
result [69–71].
Several studies were conducted on β2 agonists because they have an
anabolic effect [72,73] but long-term studies did not provide any
evidence for their effectiveness.
An open study was conducted on FSHD1 patients to analyze the
effects of methionine and folic acid, which are supposed to increase
methylation. Neither clinical effect nor DNA methylation increases
in peripheral blood lymphocytes were observed after 12 weeks of
treatment [74].
Myostatin negatively controls satellite cell proliferation and
differentiation [75]. In 2005, Wyeth laboratories started a controlled
double-blind trial for patients suffering from various types of muscular
dystrophies, including FSHD1, testing an antibody (MYO-029) against
myostatin. After 54 weeks of treatment, the trial was stopped because,
even though no sign of toxicity was reported, no effect was evident in
any of these patients [76].
In vitro studies have shown that oxidative stress plays an important
role in determining DUX4 toxicity, therefore stimulating the oxidative
stress response pathway could be beneﬁcial in FSHD [77], but no patient
data are available at the moment.
Transplantation of cultured myoblasts by intramuscular injection
has been considered for a number of dystrophies and, in particular, in
Duchenne Muscular Dystrophy (DMD). Because FSHD is characterized
by selective muscle involvement, FSHD patients display a wide spec-
trum of affected and unaffected muscles. We have demonstrated [78]
that myoblast cell cultures derived from histologically unaffected
FSHD muscles were normal in all aspects of cell proliferation and
in vitro and in vivo differentiation. We suggested that such myoblasts
could be used for autologous cell therapy in FSHD, eliminating the
need of immunosuppression and a therapeutic trial, exploring the feasi-
bility and efﬁcacy of this approach is still ongoing in our Institution.
Meanwhile, another type of myogenic mesodermal stem cell,
mesangioblast, has been considered in view of future autologous thera-
peutic trials. Mesangioblasts were shown to improvemusclemorpholo-
gy and function when injected intra-arterially in animal models of
dystrophy. Since they can be delivered through the circulation to
whole body muscles, mesangioblasts could represent a more effective
alternative for autologous cell therapy in comparison to myoblasts
that have to be injected locally. Moreover, mesangioblasts derived
from pathologically affected FSHDmuscle weremorphologically abnor-
mal and had a block in differentiation, while mesangioblasts derived
from morphologically normal FSHD muscle did not show such abnor-
malities [79]. However, recent studies analyzing the level of DUX4-ﬂ ex-
pression in affected and non-affectedmuscles and/or myogenic derived
cells showedno signiﬁcant difference in the expression of this transcript
related to the level of muscular dystrophy (Sacconi, unpublished re-
sults). Environmental or structural factors may also contribute to differ-
ent tissue sensitivities to DUX4-ﬂ expression and, consequently, they
may considerably limit the effect of autologous cell therapy.
Several groups are working on developing gene therapy for FSHD1
patients.Most of themare focused in suppressingDUX4gene expression
by using siRNA or RNA-like antisense oligonucleotides (AONs), as it has
been done in DMD. The goal is to interfere with DUX4mRNA processingand stability, or alter the splicing of the DUX4 transcript to reduce the
amount of DUX4-ﬂ in favor of DUX4-s.
In the absence of an effective etiological therapy, the correct man-
agement of symptoms and of secondary involvement is essential to
slow down disease progression in order to conserve as long as possible
functional autonomy and adequate quality of life. It is also important to
identify precociously retinal and auditory complications, to treat scolio-
sis and tomonitor respiratory insufﬁciency (especially in severe forms).
It is possible to perform surgery for winged scapula, although this
technique is still controversial.
The role of exercise inmaintaining or improvingmuscular force and/
or functional ability is still controversial, because of the lack of con-
trolled studies and because vigorous exercise could theoretically wors-
en muscular weakness inducing rhabdomyolysis. However there are
no indications that FSHDmuscle ﬁbers aremore likely tomechanical in-
jury as are dystrophies with sarcolemmal abnormalities. In fact, several
studies have shown that both strength training and aerobic exercise in
FSHD have at least a short-term beneﬁcial effect [80]. These observa-
tions were conﬁrmed in a prospective 1-year trial [81]. In a recent, un-
controlled before–after trial, we demonstrate the feasibility, safety,
and effectiveness of neuromuscular electrical stimulation strength
training in FSHD1 patients [82]. Physical therapy should promote a
non-sedentary life style, joint ﬂexibility training to avoid retractions
and improve muscle strength and aerobic capacity by mild aerobic
exercising.
Future randomized controlled studies are necessary to better deﬁne
and broaden these recommendations.
8. Open issues
Over the last decade, there were major advances in the understand-
ing of the genetic and epigenetic bases of FSHD and its pathophysiology.
Nevertheless there are important issues that are still a matter of inves-
tigation. Even though genetic and epigenetic evidence is strongly in
favor of a major role of DUX4, the exact pathophysiological mechanism
remains to be deﬁned. This knowledge is crucial to develop novel phar-
macological approaches. The bases of the selectivity of muscle involve-
ment are also largely obscure as well as of the milder phenotypes
observed in females. Variability of clinical phenotype is explained only
in part by the extent of D4Z4 contraction. The possibility that modiﬁer
genes other than SMCHD1 may contribute in worsening or improving
clinical expression of the disease is tempting and need to be further in-
vestigated. These genes may be involved in epigenetic regulation of the
D4Z4 region andmay be responsible for other forms of FSHD in aminor-
ity of patients who lack genetic diagnosis.
Understanding all these issues may contribute in developing novel
therapeutic approaches for FSHD.
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